Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Income Before Tax

Profit after all operating and non-operating items but before income tax.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$22.97M, compared with -$16.98M a year earlier. Trailing-twelve-month income before tax was -$84.53M.

Context

  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$22.97M or moves back toward the trailing-twelve-month quarterly average of -$21.13M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.97M-11.7% QoQ
Last fiscal yearDec 2025
-$78.54M-95.3% YoY
LTMMar 2026
-$84.53M-68.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-35.3%——
1 year-95.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(78.54M) USD
Year-over-year change
-95.3%

Income Before Tax vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -68.1% is the 9th highest of 10, against a peer median of +0.6%.
CRBP Competitors
Income Before Tax for CRBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$36.23M USD+33.6%—1143.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
FBRXForte Biosciences, Inc.LTM Mar 2026-$74.45M USD-70.3%——
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
ALECAlector, Inc.LTM Mar 2026-$125.22M USD-1.5%—679.9%
Peer median (excluding CRBP) —+0.6%—1764.5%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue881.71K0000
Cost of Revenue1.64M1.49M0600K0
Gross Profit(757.53K)(1.49M)0(600K)0
Gross Margin-85.9%————
Research & Development36.45M16.14M31.17M32.22M70.1M
Selling, General & Admin20.43M18.7M13.91M16.5M15.22M
Operating Expenses55.23M33.35M45.08M48.12M85.31M
Depreciation & Amortization1.64M1.49M641K600K233K
EBITDA(42.17M)(38.73M)(40.11M)(37.74M)(78.3M)
EBITDA Margin-4782.9%————
Operating Income(55.99M)(34.84M)(45.08M)(48.72M)(85.31M)
Operating Margin-6350.1%————
Interest Income0006.31M5.53M
Interest Expense1.83M2.13M2.92M1.87M0
Other Income / Expenses10.35M(7.51M)474K8.51M6.77M
Income Before Tax(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Pre-Tax Margin-5176.4%————
Income Tax Expense00000
Net Income(45.55M)(55.83M)(44.6M)(40.21M)(78.54M)
Net Margin-5166.4%————
EPS (Basic)(11.13)(10.15)(10.31)(3.68)(5.90)
EPS (Diluted)(11.13)(10.15)(10.31)(3.68)(5.90)
Weighted Avg Shares4.1M4.17M4.33M10.92M13.32M
Weighted Avg Shares (Diluted)4.1M4.17M4.33M10.92M13.32M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.